Epstein-Barr Virus and p16INK4A Methylation in Squamous Cell Carcinoma and Precancerous Lesions of the Cervix Uteri by Kim, Na Rae et al.
INTRODUCTION
The p16 gene is one of the cell cycle regulating genes and
encodes a nuclear protein, p16 which inhibits the D-type
cyclin/cyclin-dependent kinase complexes that phosphorylate
the retinoblastoma gene product (pRb), thus blocking G1-S
cycle progression (1, 2). The inactivation of p16 tumor sup-
pressor gene promotes cell proliferation, and is found in many
different types of carcinomas such as gastric carcinoma, blad-
der tumor, glioma, breast cancer and head and neck tumors
(3). There is compelling evidence that the inactivation of p16
is an important genetic event in immortalization of kerati-
nocytes (4). In previous studies of the p16 in cervical carci-
nomas, methylation specific polymerase chain reaction (PCR)
has shown a high level of methylation (1, 5), concordant with
reports that the p16 gene is frequently inactivated through
methylation rather than mutation or deletion. DNA methy-
lation is a frequent epigenetic event in many human cancers
(6, 7), and the factors inducing methylation remain unclear,
but structural abnormalities of local DNA, and exposure to
heavy metals are only known causes (8). A growing number
of cancer-related genes are being recognized for the presence
of dense methylation of cytosine in normally unmethylated
CpG-rich sequences, called CpG islands within the 5′ gene
promoter regions. 
Besides p16 gene inactivation, viral infection also partici-
pates in the dysregulation of cell cycle. A clear relationship
between human papillomavirus (HPV) and cervical squamous
cell carcinomas (SCCs) is well established; HPV-infected inva-
sive SCCs tend to express more immunoreactivity for p16
protein or p16 methylation status than do HPV-negative cer-
vical carcinomas, which is now regarded as surrogate biomark-
ers of HPV infection along with Ki-67 labeling index (5, 9,
10). Epstein-Barr virus (EBV) was suggested as another onco-
genic virus in cervical carcinogenesis, based on findings of
clonal nature of EBV in cervical carcinoma cells and the pres-
ence of EBV in precancerous lesions of the cervix (11). Since
then, much debate has been evoked because of divergent results
including a relatively high prevalence rate of EBV-positive
nonneoplastic cervical tissue, which shed doubt on the pos-
sibility. However, heterogeneous reports on lymphoepithe-
lioma-like carcinoma of the uterine cervix in Asian women
showing a higher EBV infection (12), and the co-work of HPV
and EBV cannot exclude EBV’s direct, or indirect impact
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Epstein-Barr Virus and p16
INK4A Methylation in Squamous Cell 
Carcinoma and Precancerous Lesions of the Cervix Uteri
Methylation of p16 is an important mechanism in cervical carcinogenesis. However,
the relationship between cervical squamous cell carcinoma (SCC) and Epstein-Barr
virus (EBV) remains controversial. Here, we explored whether EBV infection and/or
p16 gene inactivation would play any role in cervical carcinogenesis. Eighty-two
specimens included 41 invasive SCCs, 30 cervical intraepithelial neoplasm (CIN;
CIN 1, 11 cases, CIN II, 3 cases, CIN III 16 cases) and 11 nonneoplastic cervices.
EBV was detected by polymerase chain reaction (PCR) for EBNA-1 and in situ hy-
bridization for EBER-1. The p16 methylation-status and the expression of p16 pro-
tein were studied by methylation-specific PCR and immunohistochemistry, respec-
tively. The materials were divided into four groups: 1) nonneoplastic cervices, 2) CIN
I, 3) CIN II-III and 4) invasive SCCs. p16 methylation and p16 immunoexpressions
increased in CIN and invasive SCCs than nonneoplastic tissue. p16-methylation
and p16-immunoreactivities were higher in the EBV-positive group (p=0.009, p<
0.001) than in the EBV-negative group. EBV was detected more frequently in CIN
and SCCs than nonneoplastic cervices. In conclusion, a correlation between p16
methylation, p16 immunoreactivity and the detection of EBV strongly suggested
that the cooperation of EBV and p16 gene may play a synergic effect on cell cycle
deregulation.
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on cervical carcinogenesis (7, 11, 13). Considering that the
tumors like gastric or nasopharyngeal carcinomas, which are
known to be closely related with EBV’s oncogenic effects,
were identified in a high frequency of p16 methylation (14,
15), a close relationship exists between EBV and p16 gene.
In Korea, one study about HPB and p16 methylation has
been retrieved (16), and few studies about EBV detection or
p16 alterations in cervical carcinomas have been retrieved (17,
18). There is, however, virtually no published information on
the methylation changes during the multistage pathogenesis
of EBV-related cervical lesions. 
In this study, we explored EBV infection of the uterine
cervix with reference to p16 gene that is frequently methy-
lated in cervical carcinomas. Moreover, we investigated as to
whether the two factors play an independent or synergic role
during cervical carcinogenesis.
MATERIALS AND METHODS
Tumor samples
Eighty-two, formalin-fixed, paraffin-embedded cervical
lesions were used for immunohistochemical, polymerase chain
reaction (PCR) and in situ hybridization (ISH) studies. Mate-
rials were obtained from the pathology files of Anam Hospi-
tal, Korea University College of Medicine between 1995 and
2001. Samples included 41 cases of SCCs, 30 cases of cervical
intraepithelial neoplasms (CIN 1; 11 cases, CIN II; 3 cases,
CIN III; 16 cases), and 11 cases of non-neoplastic cervices.
DNA extraction
DNA samples were extracted from several serial six  m-
thick paraffin sections as previously described (19). Briefly,
tissue samples were treated with lysis buffer containing 100
g/mL proteinase K (Merck, Darmstadt, Germany) at 48℃
for 48 hr. DNA extraction was then performed by phenol/
chloroform treatment and precipitation with ethanol. The
quality of the DNA extracted was confirmed with a beta-globin
gene-specific primer pair (BGLO1 and BGLO2), which ampli-
fies 110 base pairs. 
Bisulfite modification and methylation-specific polymerase
chain reaction (MSPCR) for detecting p16
DNA methylation patterns in the CpG islands of the p16
were determined by MSPCR assays by Herman et al. (20).
Briefly, 200 to 300 ng DNA was first treated with 3 mol/L
sodium bisulfite to convert nonmethylated cytosine to uracil
residues. As a diagnostic step, we used heminested PCR to
increase the sensitivity of detection with primers p16M/p16
mol/L2r for the first and p16Mf/p16Mr for the second step
under conditions as described. Base sequences of used primers
are as follows;
p16-methylated (p16-M): forward; 5′ TTA TTA GAG GGT
GGG GGCG GATCGC 3′
reverse; 5′ GACCCCGAACCGCGACCGTAA 3′
p16-unmethylated (p16-U): forward; 5′ TTATTAGAGGG-
TGGGGTGGATTGT 3′
reverse; 5′ CAACCCCAAACCACAACCATAA 3′
In all cases, the amplification of nonmethyl-specific alleles
served as controls for the efficiency of cytosine conversion and
DNA quality. Controls without DNA and positive controls
for U and M reactions were performed for each set of PCRs.
The PCR product was visualized in agarose gels stained with
ethidium bromide under ultraviolet illumination. DNA me-
thylation was determined by the presence of a150-bp and
151-bp fragments in those samples amplified with the p16-
M and p164-U primers, respectively. Positive PCR products
in p16-M and/or p16-U are interpreted as methylated, and
PCR products in only p16-U are interpreted as unmethylat-
ed status.
Immunohistochemistry for p16
Immunohistochemical staining of p16 was performed with
p16 monoclonal antibody (SC 468; Santa Cruz Biochemicals,
CA, U.S.A.) diluted at 1:50. Immunodetection was performed
with biotinylated antimouse immunoglobulins, followed by
peroxidase-labeled streptavidin, LSAB-2 (DAKO, Glostrup,
Denmark) with diaminobenzidine chromogen as the substrate.
Each section was counterstained with hematoxylin. Incuba-
tion omitting the specific antibody, as well as with unrelated
antibodies, was used as a control of the technique. A positive
control was included with each slide. The results were inter-
preted as positive according to the established criteria by Ger-
adts et al. (21).
PCR for detection of EBV
To examine the presence of EBV DNA in the samples, 0.1
g DNA from a cervical sample was subjected to PCR anal-
ysis using EBNA-1 primers which target a 138 base pair seg-
ment of the Bam H1W internal repeat (IR 1) region described
by Coates et al. (22). Base sequences of primers were as follows;
EBNA-1 Forward : 5′ TGATAACCATGGACGAGGAC 3′
Reverse : 5′ CTTCAAGTTGCATTGGCTGC 3′
Thirty-five PCR cycles at 95℃ for 7 min, at 94℃ for 1
min, at 58℃ for 40 sec, and at 72℃ for 40 sec were carried
out. And it was carried out at 72℃ for 7 min Polymerase
chain reaction was carried out in duplicate or triplicate. The
amplified products were run on 2% Nuieve/agarose gel and
were transferred onto a Hybond N+ membrane (Amersham
Biosciences, Uppsala, Sweden). They were stained with ethid-
ium bromide and examined under ultraviolet illumination.
As a positive control of EBNA-1, B95-8 cell line was used.638 N.R. Kim, Z. Lin, K.R. Kim, et al.
In situ hybridization (ISH) for EBV
EBV ISH was performed using oligonucleotide probes
against EBV-encoded RNA-1 (EBER-1; Novocastra, New-
castle, U.K.), following previously reported procedures (23).
EBER-1 positivity was shown by latently EBV-infected cells.
Briefly, EBER-1 ISH was performed on each case using digoxi-
genin-labeled riboprobes produced from plasmid templates.
A step-by-step description of one of the testing protocols,
which uses EBER-1 was executed on each case and hybridized
overnight. RNase was used to facilitate the washing away of
unbound probe and a detection system based on the applica-
tion of antibody to digoxigenin was linked to alkaline phos-
phatase. It was counterstained with hematoxylin. Known
cases of EBV-harboring tonsils were used as controls. Strong
signals of the nuclei were interpreted as positive results.
Data analysis
We divided the cases into four groups as follows: non-neo-
plastic normal cervical tissue, low grade dysplastic lesions
(cervical intraepithelial neoplasm, CIN I), high grade lesions
(CIN II and III) and invasive SCCs. Subsequently, we com-
pared EBV infection with p16 methylation and p16 protein
expression. Statistical analysis was performed by means of
SPSS software version 10. The associations between the dis-
crete variables were assessed using McNemar’s exact test and
chi-square test. The same tests were used to evaluate the influ-
ence of the tumor grade of CIN. Differences were considered
statistically significant for p<0.05.
RESULTS
All the results of p16 methylation, p16 protein expression,
EBNA-1 PCR and EBER-1 ISH of the eighty-two cases were
shown in Table 1.
p16 methylation status
Non-neoplastic cervices showed unmethylation in all the
cases, but 40% (12/30) of cervical intraepithelial neoplasms
and 61% of invasive squamous cell carcinomas (25/41) showed
p16 methylation (p=0.003, Fig. 1, Table 1). There existed
statistical differences among CIN I, II and III (p=0.03, data
not shown), while the advanced stage of squamous cell car-
cinomas (stage IIb) revealed a higher p16 methylation rate
than the early stage (I, IIa) of squamous cell carcinomas, how-
ever, the results were not statistically significant (p=0.107,
Table 2). 
Immunohistochemistry for p16 protein
Non-neoplastic cervices were immunonegative for p16 pro-
tein except for basal cells that are known to normally express
p16 protein, but 53% of cervical intraepithelial neoplasm
(16/30 cases) and 68.3% of invasive squamous cell carcino-
mas (28/41) expressed p16 protein. These results were sig-
p16 MSPCR
No. 
(%)
p
value
p16 IHC
No. 
(%)
p
value
EBNA-1 PCR
No. 
(%)
p
value
EBER-1 ISH
No. 
(%)
p
value
Normal 0/11 0.003 0/11 0.001 1/11 0.33 0 0.111
(n=11) (0%) (0%) (9.1%) (0%)
CIN I  5/11  4/11  4/11  2/11 
(n=11) (45.5%) (36.4%) (36.4%) (18.2%)
CIN II +III  7/19  12/19  7/19  4/19 
(n=19) (36.8%) (63.2%) (36.8%) (21.1%)
SCC 25/41  28/41 15/41 14/41 
(n=41) (61%) (68.3%) (36.6 %) (34.1%)
Table 1. Results of prevalence of EBV, p16 hypermethylation
and p16 immunoreactivities
PCR, polymerase chain reaction; ISH, in situ hybridization; CIN, cervical
intraepithelial neoplasm; SCC, squamous cell carcinoma; MSPCR, methy-
lation-specific PCR; IHC, immunohistochemistry. 
p16 MSPCR
FIGO
stage No. 
(%)
p
value
p16 IHC
No. 
(%)
p
value
EBNA-1 PCR
No. 
(%)
p
value
EBER-1 ISH
No. 
(%)
p
value
IA (n=8) 3/8  0.107 4/8 0.192 2/8 0.163 2/8  0.314
(37.5%) (50%) (25%) (25%)
IB (n=17) 8/17  12/17  9/17  7/17 
(47.1%) (70.6%) (52.9%) (41.2%)
IIA (n=9) 7/9 8/9 4/9 4/9 
(77.8%) (88.9%) (44.4%) (44.4%)
IIB (n=7) 7/7 3/7 0/7 1/1 
(100%) (42.9%) (0%) (100%)
Table 2. Comparison of p16 methylation status and EBV status
according to the tumor stages
MSPCR, methylation-specific PCR; IHC, immunohistochemistry; PCR,
polymerase chain reaction; ISH, in situ hybridization.
Fig. 1. Methylation status of the p16 gene detected by methylation-
specific PCR. Lane 1-3, CIN; lane 4-6, cervical carcinoma; lane 7,
normal cervical tissue; M, Molecular weight marker; lanes m, reac-
tions using p16-M primers specific for the methylated CpG sites.
lanes u, reactions using p16-U primers specific for the unmethy-
lated CpG sites.
151 bp
Mm um u m um u m umum u
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nificantly different among the four groups (p=0.001, Table
1, Fig. 2). However, no differences existed among the three
grades of cervical intraepithelial neoplasms (p=0.600, data not
shown). In comparison of invasive carcinomas according to
the stage, there was a higher expression rate in more advanced
stages, but no statistically significant differences existed (p=
0.192, Table 2).
EBV detection
EBV was detected by EBNA-1 PCR in 9.1% of non-neo-
plastic cervical tissue (1/11), 36.7% of cervical intraepithe-
lial neoplasm (11/30) and 36.6% of invasive squamous cell
carcinomas (15/41) (Fig. 3). There was no statistically signif-
icant difference in the detection rate of EBV among the four
groups (p=0.331, Table 1), whereas a significant difference
existed between the two groups (non-neoplastic cervices vs.
precancerous CIN and cervical cancers, p=0.040, data not
shown). There were no statistical differences among the grades
of CIN (p=0.747, data not shown).
EBNA-1-positive cervical lesions showed a 70.4% (19/27)
positive detection rate in EBER-1 ISH (Fig. 4). In compari-
son of invasive carcinomas according to the tumor stages, the
EBV detection rate did not show a statistically different rate
between each stage (p=0.124, Table 2).
Exact test of concordance of p16 MSPCR with the
immunohistochemistry of p16 protein, and the EBV detec-
tion rate
By McNemar’s exact test, p16 MSPCR and the immuno-
histochemical results were proven to be concordant, while the
detection rate of EBV was different between in situ hybridiza-
tion and PCR.
A B C D
Fig. 2. Immunohistochemistry for p16. Focal nuclear staining in the basal cells of the non-neoplastic cervical tissue (A, p16 immunostain,
×200), CIN I (B, p16 immunostain, ×200), CIN III (C, p16 immunostain, ×200) and intense nuclear staining in invasive squamous cell
carcinoma (D, p16 immunostain, ×400).
Fig. 3. Analysis of EBV using EBNA-1 primer. Lane 1-2, Normal
cervical tissue; lane 3-6, Squamous cell carcinoma; lane 7-9, CIN;
lane N, Negative control; lane C, Positive control; M, molecular weight
marker.
138 bp
M123456789NC
PCR, polymerase chain reaction; MSPCR, methylation-specific PCR; M,
methylated; U, unmethylated.
p16 MSPCR
M U Total p value
p16 immunohisto-
chemistry
M U Total p value
EBV + 23 15 38 0.009 29 9 38 0.001
detected - 14  30  44 15 29 44
by PCR Total 37 45 82 44 38 82
Table 3. Comparison of p16 methylation status and p16 immu-
noreactivity between EBV-positive and -negative cervical lesions640 N.R. Kim, Z. Lin, K.R. Kim, et al.
Correlation among p16 methylation, p16 immunoreactivi-
ty and EBV detection
The cervical lesions positive for EBV by PCR showed a
higher rate of p16 methylation and/or p16 immunopositivi-
ty, which was statistically significant (Table 3).
DISCUSSION
In this study, 61% of squamous cell carcinomas of the uter-
ine cervix showed p16 methylation, which was higher than
31% in the report of Wong and his colleagues (2). Cervical
carcinomas are known to show a high proportion of p16 methy-
lation, while other gynecological malignancies have variable
frequencies (24). Sano et al. (4) reported that invasive squa-
mous cell carcinoma and CIN lesions (low and high grades)
exhibited higher p16 immunoreactivity than non-neoplastic
cervices. Based on the results that dysplastic lesions progressed
toward carcinomas with increasing p16 methylation, methy-
lation has been thought to play a critical role in oncogenesis
as in lymphoma or carcinomas of other organs (25). However,
the frequency of p16 methylation between early and advanced
stages showed no statistically significant difference, which
is quite different from those of the tumors in the head and
neck, breast or bladder (2, 26, 27). This result may indicate
that early cervical carcinogenesis requires p16 methylation,
but additional molecular genetic events are necessary for its
progression.
Variable data on p16 immunoreactivities and cervical car-
cinomas have been described in the literature; most of them
reported loss of p16 protein (28), while some reported the
reexpression of p16 protein (29). In our study, dysplastic cer-
vical epithelium and squamous cell carcinomas showed a
higher expression of p16 protein in the cervical epithelium,
which contradicts most of the previous studies, but fits well
with that of Klaes et al. (29). The statistically concordance
despite discrepancy in individual comparison between p16
immunohistochemistry and p16 MSPCR in this study indi-
cates that the former may employ an inexpensive screening
method to detect squamous cells showing early dysplastic
changes. Interpretation of immunoreactivity for p16 protein
has some limitations because p16 expression is variable in
normal, dysplastic epithelium and neoplastic tissue; basal layer
of nonneoplastic exocervix expresses weak and focal nuclear
stainability (30). Theoretically, p16 protein should be expressed
only in the nuclei but cytoplasmic staining pattern was occa-
sionally observed, and its significance remains unclear. Cyto-
plasmic immunoreactivity may be induced by a nonspecific
uptake or may be caused by functional heterogeneity (21).
Some of the cultured cells pertaining to p16 gene show nuclear
negativity but with variable cytoplasmic reactivities, or cyto-
plasmic p16 detected by immunoblotting may indicate that
this cytoplasmic localization of p16 is ‘‘dormant’’ like that
of the tumor suppressor gene, which has functions different
from the nuclear one (31). A discrepancy in the results between
the two detection methods for p16 inactivation was noted
in our series. MSPCR has been known to be more sensitive
and specific than Southern hybridization (20). In contrast,
immunohistochemistry using p16 monoclonal antibody is
simple and useful but has several technical limitations. For
example, p16 protein is prone to break during the process-
A B C D
Fig. 4. (A) EBER-1 signals detected by in situ hybridization (×200). No signals are detected in squamous cell carcinoma. (B) In CIN I, some
of the dysplastic cells show nuclear staining (×200). (C) In CIN III, dysplastic cells show nuclear staining (×400). (D) In squamous cell
carcinoma, tumor cells and some intervening lymphocytes show nuclear staining for EBER-1 (×400).EBV and p16 Methylation in Cervical Cancer 641
ing, and heterogeneous immunoreactivity in nonneoplastic
tissue could cause confusion during interpretation. Progres-
sive increase of p16 immunoreactivity and methylation were
observed at carcinomatous progression. Timmermann et al.
(32) demonstrated that epithelial cells gained increased activ-
ity of beta-galactosidase that is associated with senescence and
produced p16 protein with no normal suppressor function.
The reexpression of this incomplete protein detected by
immnohistochemical method may be explained (33).
In this study, 60.5% of EBV-positive cervical tissues were
p16-methylated, whereas 68.2% of EBV-negative cervical
tissues were p16-unmethylated. These results were similar
to those of nasopharyngeal undifferentiated carcinoma or EBV-
positive gastric carcinomas, where there was likewise a trend
toward an association between EBV infection and loss of p16
expression. One possible explanation for the association of
p16 loss and EBV infection is that EBV-infected tumors could
have a higher growth rate and therefore a greater opportunity
to accumulate more mutations, including those of p16. In
this study, we confirmed EBV infection by PCR and ISH.
There was disconcordance between the results through EBV
PCR and ISH. In general, the amplification of DNA through
PCR was possible even in one viral particle, thus, theoreti-
cally it is a more sensitive method than ISH (9). In practice,
a sensitive and specific practical method for detecting EBV
is ISH (34). Cases of EBV-negativity by PCR but EBV-pos-
itive reaction by ISH in this study, seemed to be caused by
insufficient amplification process. In this study, 39% of SCCs
were EBV-positive, which was not a high frequency compared
to non-neoplastic tissues or CIN. However, EBV-positive car-
cinomas showing a high rate of p16 methylation suggested
that EBV alone does not play a key role in uterine cervical
squamous epithelium, rather it may be involved in the earliest
step of oncogenesis, which is somewhat dissimilar to that of
nasopharyngeal carcinoma or Burkitt’s lymphoma. Recent
development of molecular genetics for carcinogenesis and
virus, methylation of CpG islands possessing p16 is induced
by the integration of viral DNA into host cells (34, 35). It
was suggested that methylation of foreign DNA integrated
with host DNA or adjacent host DNA, especially cell cycle
regulatory site is the first step of carcinogenesis (36), which
is similar to those of SV40 in relation to malignant mesothe-
lioma or EBV in relation to EBV-positive gastric carcinomas
(15, 37). Methylation of EBV genome inhibits suppression
of immunodominant viral antigen by EBV-infected tumor
cells and escapes immunosurveillance (15). Pharmacological
blocking by methylation inhibitor causes tumor suppressor
gene to be protected from aberrant methylation, might finally
gain its own function, which the tumor cells expose immuno-
surveillance system. Actually, clinical application is now being
attempted (38). On this mechanism, the relationship between
EBV infection and p16 methylation plays a role in the early
change of cervical carcinogenesis, and may provide promise
for future treatments.
In conclusion, we did not find an association between p16
methylation status and stage. These observations well corre-
sponded to the fact that p16 inactivation is an early epigenetic
event in cervical cancer. A more intense reactivity of p16 pro-
tein was associated with p16 methylated status in this study,
which might imply that p16 immunoreactivity represents
the reactivation of senescent p16 protein in cancers, keeping
with a previous report of cervical carcinoma, but differs from
the correlation with the advanced stage of cervical SCC in the
earliest study of Wong et al. (2). Although our findings need
to be extended to a larger series, the pattern of p16 methyla-
tion in cervical lesions with or without EBV-infection may
help identify subgroups at increased risk for accelerated pro-
gression. 
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